AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions

🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with ...